Abstract:The ADA recommends to screen for NASH and liver fibrosis individuals with type 2 diabetes (T2DM), obesity (OB) and/or elevated alanine aminotransferase (ALT). However, recent studies have questioned the clinical value of measuring ALT and AST for the detection of patients at risk of nonalcoholic fatty liver disease (NAFLD) or advanced liver fibrosis or cirrhosis. The aim of this study was to assess the clinical value of ALT and AST ≥40 IU/L, or their lower cut-offs ≥30 IU/L as recommended by recent AACE guidelines, to screen populations at risk. To this end, we recruited 714 participants (age: 56 ± 11 years, male: 42%; BMI: 30.8 ± 6.5 kg/m2; T2DM: 35%; A1c: 6.0 ± 1.2%) from primary care or endocrinology clinics, unaware of having NAFLD/fibrosis. Screening for NAFLD included laboratory tests and imaging with elastography (steatosis by controlled attenuation parameter [CAP]; fibrosis by liver stiffness measurement [LSM]). Elevated transaminases were more common in patients with vs. without T2DM, with ALT ≥40 IU/L occurring in 13% vs. 8% and AST in 9% vs. 3% of patients (both p<0.05). If using a cutoff of ≥30 IU/L: 25% vs. 18% and 20% vs. 13%; respectively (both p<0.05). Elevated ALT ≥30 IU/L was the highest in patients with T2DM and OB (n=164) vs. controls (without T2DM or OB; n=269; 27% vs 15%; p=0.02). The sensitivity for diagnosing steatosis by ALT or AST was very low, with ALT and AST ≥40 IU/L present in only 16% and 9%, respectively. However, steatosis by imaging (CAP) was often present if ALT or AST were high (81 and 90%, respectively). An ALT ≥40 IU/L was also not useful for diagnosing patients with fibrosis of any stage (LSM ≥7.0), missing the diagnosis in 63% of patients, and this did not improve when examining only those with more advanced fibrosis (≥F3) being elevated in only 40%. Conclusions: Plasma aminotransferases are of limited diagnostic value when screening patients with T2DM for NAFLD or fibrosis. This supports the ADA recent guidelines for using FIB-4 and additional noninvasive testing for screening. Disclosure A. Ortiz Rocha: None. E. Godinez Leiva: None. S. Kalavalapalli: None. R. Lomonaco: None. S.S. Shetty: None. S.A. Marangi: None. E. Valdez Saenz: None. S. Shrestha: None. M.A. Gonzalez: None. X. Chi: None. M.J. Gurka: None. D. Barb: None. K. Cusi: Research Support; Echosens, Inventiva. Consultant; Poxel SA. Research Support; LabCorp, Zydus. Consultant; Altimmune, Arrowhead Pharmaceuticals, Inc., AstraZeneca, 89bio, Inc., Bristol-Myers Squibb Company, Lilly, Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Medscape, Myovant, Novo Nordisk, ProSciento, Quest Diagnostics, Sagimet, Sonic Incytes, Terns. Funding National Institutes of Health (R01120331-01A1)

ALT poorly predicts Nonalcoholic Fatty Liver Disease (NAFLD) and liver fibrosis as determined by vibration-controlled transient elastography in adult National Health and Nutrition Examination Survey 2017–2018

Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis

Usefulness Of Controlled Attenuation Parameter And Liver Stiffness Measurement For Detecting Increased Arterial Stiffness In Asymptomatic Populations In China

Relationship Between Alanine Aminotransferase Levels and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease

Comparison of Pathological Characteristics in Patients with Non-Alcoholic Fatty Liver Disease under Diverse Alanine Transaminase Upper Limits of Normal

Elevated ALT/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States

Prevalence and Factors Associated with NAFLD Detected by Vibration Controlled Transient Elastography among US Adults: Results from NHANES 2017-2018.

Non-ALT Biomarkers for Markedly Abnormal Liver Histology among Chinese Persistently Normal Alanine Aminotransferase-Chronic Hepatitis B Patients.

1342-P: Are Plasma Aminotransferases of Value in Screening Patients with T2DM for NAFLD or Fibrosis?

[Accuracy of FibroScan for the Diagnosis of Liver Fibrosis Influenced by Serum Alanine Aminotransferase Levels in Patients with Chronic Hepatitis B].

Alanine Aminotransferase-Based Algorithms of Liver Stiffness Measurement by Transient Elastography (fibroscan) for Liver Fibrosis in Chronic Hepatitis B.

Lower Alanine Aminotransferase Levels Are Associated with Increased All-Cause and Cardiovascular Mortality in Nonalcoholic Fatty Liver Patients.

Upper limits of normal for alanine aminotransferase activity in the United States population

Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values

Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implications

Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis

Impact of Controlled Attenuation Parameter on Detecting Fibrosis Using Liver Stiffness Measurement.

Impact of Mild to Moderate Elevations of Alanine Aminotransferase on Liver Stiffness Measurement in Chronic Hepatitis B Patients During Antiviral Therapy

FibroScan Predicts Liver Fibrosis Progression in Chronic HBV Infection Patients with No Clear Indication for Antiviral Therapy: A Retrospective Cohort Study

Relevance of vitamin D on NAFLD and liver fibrosis detected by vibration controlled transient elastography in US adults: a cross-sectional analysis of NHANES 2017–2018

Shear Wave Elastography for Liver Fibrosis in Chronic Hepatitis B: Adapting the Cut-Offs to Alanine Aminotransferase Levels Improves Accuracy.